News
Biogen, Denali pull Parkinson's drug after failed trial
Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
R&D
Why UCB bet a billion dollars on cell therapy for epilepsy
UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
News
Lilly's 'triple G' retatrutide aces crucial obesity trial
Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
News
Infex chases after Insmed with bronchiectasis trial win
UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.
R&D
Bridging ethics and efficacy in IRB review of vaccine trials
Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
